Data completeness
3/8 — Basic
CANDEX (nystatin) by R-Pharm US is clinical pharmacology nystatin acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Approved for candidiasis, oral, hiv infection, age-related macular degeneration.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CANDEX (nystatin) is a topical antifungal lotion that binds to fungal cell membrane sterols, disrupting membrane permeability and causing leakage of intracellular components. It is indicated for oral candidiasis, with off-label exploration in HIV infection and age-related macular degeneration. Nystatin demonstrates minimal systemic absorption when applied topically, making it a localized treatment option.
Pre-Launch
Pre-launch stage indicates emerging commercial team building; limited current market presence suggests opportunity for greenfield product development and market establishment roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Nystatin acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is absorbed very sparingly following oral administration, with no detectable blood levels when given…
Worked on CANDEX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.